Royalty Pharma (NASDAQ:RPRX – Get Rating) will announce its earnings results before the market opens on Thursday, May 5th. Analysts expect the company to announce earnings of $0.73 per share for the quarter. Investors interested in participating in the company’s conference call can do so using this link.
Royalty Pharma (NASDAQ:RPRX – Get Rating) last issued its earnings results on Tuesday, February 15th. The biopharmaceutical company reported $0.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.79 by $0.01. The business had revenue of $543.00 million for the quarter, compared to analyst estimates of $543.50 million. Royalty Pharma had a net margin of 27.07% and a return on equity of 17.29%. During the same quarter in the prior year, the business posted $0.28 EPS. On average, analysts expect Royalty Pharma to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.
Shares of Royalty Pharma stock opened at $42.99 on Thursday. The firm has a market cap of $26.10 billion, a PE ratio of 42.15, a price-to-earnings-growth ratio of 1.25 and a beta of 0.74. The firm’s 50-day simple moving average is $39.98 and its 200-day simple moving average is $39.65. The company has a debt-to-equity ratio of 0.69, a quick ratio of 16.81 and a current ratio of 16.81. Royalty Pharma has a 1 year low of $34.86 and a 1 year high of $47.10.
Several equities research analysts recently weighed in on the stock. JPMorgan Chase & Co. upgraded shares of Royalty Pharma from a “neutral” rating to an “overweight” rating and set a $50.00 price objective on the stock in a research note on Thursday, April 14th. They noted that the move was a valuation call. StockNews.com assumed coverage on shares of Royalty Pharma in a research note on Thursday, March 31st. They set a “hold” rating on the stock. Zacks Investment Research lowered shares of Royalty Pharma from a “hold” rating to a “sell” rating in a research note on Wednesday, January 26th. Morgan Stanley upgraded shares of Royalty Pharma from an “equal weight” rating to an “overweight” rating and increased their price objective for the stock from $46.00 to $48.00 in a research note on Wednesday, April 6th. Finally, The Goldman Sachs Group assumed coverage on shares of Royalty Pharma in a research note on Wednesday. They set a “buy” rating and a $56.00 price objective on the stock. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, Royalty Pharma has an average rating of “Buy” and an average target price of $48.83.
In related news, Director Henry A. Fernandez acquired 32,500 shares of the firm’s stock in a transaction dated Thursday, February 24th. The stock was acquired at an average cost of $37.49 per share, for a total transaction of $1,218,425.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Rory B. Riggs sold 129,222 shares of the stock in a transaction that occurred on Friday, March 18th. The shares were sold at an average price of $39.55, for a total transaction of $5,110,730.10. The disclosure for this sale can be found here. Insiders sold 229,089 shares of company stock valued at $8,982,936 over the last quarter. Insiders own 25.86% of the company’s stock.
Hedge funds have recently added to or reduced their stakes in the stock. LPL Financial LLC acquired a new stake in Royalty Pharma during the fourth quarter valued at approximately $308,000. Stifel Financial Corp lifted its stake in Royalty Pharma by 117.1% during the fourth quarter. Stifel Financial Corp now owns 12,041 shares of the biopharmaceutical company’s stock valued at $480,000 after purchasing an additional 6,495 shares during the last quarter. OLD Mission Capital LLC purchased a new stake in shares of Royalty Pharma in the 3rd quarter valued at approximately $1,211,000. Schonfeld Strategic Advisors LLC purchased a new stake in shares of Royalty Pharma in the 4th quarter valued at approximately $2,443,000. Finally, Privium Fund Management UK Ltd purchased a new stake in shares of Royalty Pharma in the 4th quarter valued at approximately $9,739,000. 43.78% of the stock is owned by institutional investors and hedge funds.
About Royalty Pharma (Get Rating)
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.
- Get a free copy of the StockNews.com research report on Royalty Pharma (RPRX)
- Xerox Holdings Stock is a Value Play
- Carl Icahn Buys More Xerox
- The Kraft Heinz Turnaround Story Gains Momentum
- Microsoft (NASDAQ: MSFT) Saves The Day, For Now
- Las Vegas Sands Stock Could be a Winning Bet Down Here
Receive News & Ratings for Royalty Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Royalty Pharma and related companies with MarketBeat.com's FREE daily email newsletter.